InvestorsHub Logo
Followers 86
Posts 12714
Boards Moderated 0
Alias Born 10/12/2010

Re: honestabe13 post# 210817

Friday, 03/13/2015 12:05:02 PM

Friday, March 13, 2015 12:05:02 PM

Post# of 345995

i suspect mlv's market cap target did not change!



I understand but.. and sorry for being a pain in the A$$ lol but I just feel strongly that no matter what an analyst placed for a price target prior, that after yesterdays conference call that (even with dilution of shares) those same analyst must see the potential, must see the broad clinical pipeline..etc..etc..

and finally, these analysts "MUST" understand that small biotechs cave into weak partnership deals because the small biotechs have no other choice.

Peregrine has another choice, they can say no, no and again no, because they have the foundation in PS Targeting that is required across the entire spectrum of medicine and they don't own 10% or 40% or just 75% of the pipeline. They own 100%. This is unheard of in a small biotech moving forward and growing. It simply just does not, ever, never happen.

Now if analysts don't realize this now, they are not so analytic.

I have an analogy and no beach or girls or glamorous as CP's : ) .. but lets take that car driving to the beach!

Now, how may people want into a car dealership to buy a car ? they simply think the dealer is being truthful and offering the best deal

Now, how many people have walked into the car dealership to buy a car but have done due diligence on what they should pay? so they walk away and get a call and settle on a little better price

Now, how many go to dozens of dealerships and ask dozens of questions on the same model, same color..etc and then go back a 2nd time to each of those dealerships to talk them down and still say no, no , no and walk away when "ONE" of those dealerships call back and finally realize this guy has done his homework and give him the best deal?

What Peregrine is doing is what "NO SMALL BIOTECH" has ever done with Big Pharma in making and striking a deal. They are not settling for what Big Pharma is used to dishing out and they are not quitting on sabotage like acts. They recovered and fighting back and damn, they will out maneuver Big Pharma this time.

Preferred shares - Big Pharma never had to worry about this

Collaborations of PPHM style - Big Pharma never dealt with this

Feds/Investigations & everyone watching - Big Pharma not used to this

Full manufacturing capabilities - Big Pharma not used to this

DMC monitoring live and 2 look-ins ? Damn, this is when people must realize that Big Pharma is out of their safety zone and as said, some Big Pharma empires beginning to crumble as no one has ever sat opposite of that conference table with as much leverage as Peregrine today has.

"Bavituximab is a first-in-class phosphatidylserine (PS)-targeting monoclonal antibody that is the cornerstone of a broad clinical
pipeline."
-- Big Pharmas nightmare... unless they are fortunate enough to have The Bavi Edge!

Volume:
Day Range:
Bid:
Ask:
Last Trade Time:
Total Trades:
  • 1D
  • 1M
  • 3M
  • 6M
  • 1Y
  • 5Y
Recent CDMO News